Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 2:56 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 108 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Real-world, non-interventional Clear all

Conditions: Patients at Risk for Developing Contrast-induced Nephropathy
Interventions: DyeVert™ Contrast Reduction Systems; Device
Lead sponsor: Osprey Medical, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 10,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 11
States / cities: Hartford, Connecticut • Hialeah, Florida • Atlanta, Georgia + 7 more

Conditions: Post Traumatic Stress Disorder
Interventions: CPT Skills, Cognitive Processing Therapy, Present Centered Therapy, Shared Decision Making, Measurement Based Care; Behavioral
Lead sponsor: United States Department of Defense; Federal
Eligibility: 18 Years and older
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 4
States / cities: Phoenix, Arizona • New Orleans, Louisiana • Charleston, South Carolina + 1 more

Conditions: Chronic Spontaneous Urticaria
Interventions: Not listed
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 3,280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Kirksville, Missouri

Conditions: Autism Spectrum Disorder
Interventions: STRW-T, PEERS-T; Behavioral
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 15 Years to 21 Years
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 2
States / cities: Carrboro, North Carolina • Cincinnati, Ohio

Conditions: Venous Thromboembolism
Interventions: Not listed
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 3 Months to 12 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 10
States / cities: La Jolla, California • San Diego, California • New Haven, Connecticut + 7 more

Conditions: Transthyretin Amyloidosis, ATTR-CM, ATTRv-PN, ATTR, ATTR-Mixed, hATTR
Interventions: Treatment of transthyretin (ATTR) amyloidosis in observational study setting; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 1,850 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 33
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 24 more

Conditions: Non-Valvular Atrial Fibrillation
Interventions: Not listed
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 466,991 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Advanced/Metastatic HER2-negative Breast Cancer
Interventions: No drug; Other
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 1,415 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Narcolepsy
Interventions: Transition from Xyrem to Xywav; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Metastatic HER2+ Advanced Breast Cancer
Interventions: Tucatinib, Trastuzumab, Capecitabine; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetes Mellitus, Type 2
Interventions: BT-001, Control App; Behavioral · Other
Lead sponsor: Better Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 3
States / cities: Aurora, Colorado • New Orleans, Louisiana • Durham, North Carolina

Conditions: Non-small Cell Lung Cancer
Interventions: Cisplatin, Carboplatin, Pemetrexed, Pembrolizumab, Abraxane, Paclitaxel; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 318 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 11
States / cities: Tampa, Florida • Baton Rouge, Louisiana • Baltimore, Maryland + 5 more

Conditions: Hypertension, High Blood Pressure
Interventions: BPCARE Intervention; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 21 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 2
States / cities: San Diego, California

Conditions: Cardiometabolic Syndrome
Interventions: Educational Materials and Chronic Disease Management Test (CDMT); Other
Lead sponsor: Qure Healthcare, LLC; Industry
Eligibility: Not listed
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Rheumatoid Arthritis
Interventions: Non-Interventional; Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 5,800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Alzheimer's Disease
Interventions: No Intervention; Other
Lead sponsor: Eisai Korea Inc.; Industry
Eligibility: 19 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Nutley, New Jersey

Conditions: Non-Muscle Invasive Bladder Neoplasms
Interventions: Not listed
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 23
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 19 more

Conditions: Stroke, Chronic Phase of Disease
Interventions: Strategy Training Only, Strategy Training embedded with Acceptance and Commitment Therapy Principles; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Major Depressive Disorder, MDD, Depression
Interventions: Virtual Reality Behavioral Activation, Behavioral Activation in real-life; Device · Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Hormone-receptor-positive Breast Cancer, HER2-low Breast Cancer, HER2-negative Breast Cancer
Interventions: No drug; Other
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 927 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Colitis, Ulcerative
Interventions: Etrasimod; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 26
States / cities: Mesa, Arizona • La Jolla, California • Los Alamitos, California + 20 more

Conditions: ATTR Amyloidosis
Interventions: no intervention; Other
Lead sponsor: AstraZeneca; Industry
Eligibility: Not listed
Enrollment: 52,121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Eden Prairie, Minnesota

Conditions: Drug Resistant Epilepsy, Refractory Epilepsy
Interventions: Participants are not assigned an intervention as part of the study.; Other
Lead sponsor: NeuroOne Medical Technologies Corporation; Industry
Eligibility: Not listed
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Miami, Florida • Livingston, New Jersey • New Brunswick, New Jersey

Conditions: Telemedicine
Interventions: Enhanced Usual Care, Super Supporter Support; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 1,111 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 2
States / cities: Charlotte, North Carolina • Winston-Salem, North Carolina

Search by objective public record fields.

DyeVert™ System for Contrast Monitoring in At-Risk Patients Undergoing Angiography: A Real-World Registry

Reducing Dropout and Improving Outcomes From PTSD Therapy: When to Switch Therapies or Stay the Course

Remibrutinib in Real-world Clinical Practice

STRW-T Intervention for Autistic Adolescents in 11th and 12th Grade

A Study in the United Sates That Looks at the Safety and Effectiveness of Pradaxa Pellets in Children Aged 3 Months to Less Than 12 Years Who Need Treatment of a Blood Clot or Who Have Had a Blood Clot and Are at Risk of Developing Another Blood Clot

Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis

Clinical and Economic Outcomes of Oral Anticoagulants in Non-valvular Atrial Fibrillation

Real-World Outcomes of Patients With Metastatic Breast Cancer After Treatment With First-Line ET+CDK4/6i

A Patient-Centric, Prospective, Observational, Non-Interventional Switch Study of XYWAV in Narcolepsy

Real World-clinical Outcomes of Tucatinib, Trastuzumab, and Capecitabine Following Trastuzumab Deruxtecan (T-DXd) for the Treatment of HER2-positive Metastatic Breast Cancer.

Digital Therapeutic Based Investigation to Improve Glycemic Control in Patients With Type 2 Diabetes and Residual Hyperglycemia on Stable Medical Therapy

Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC

Blood Pressure Care for Advancing Real-World Evidence (BPCARE)

Establishing Clinical Utility Evidence for Chronic Disease Management Testing

Safety Study of Abatacept in Rheumatoid Arthritis Participants

A Postmarketing Study of LEQEMBI in South Korean Participants With Alzheimer's Disease

A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) in the United States

Rehabilitation Strategies for Social Participation in Chronic Stroke Survivors

Virtual Reality Behavioral Activation: An Intervention for Major Depressive Disorder

Study of Predictors of Clinical Outcomes in Patients With HR+ and HER2-low/Negative Breast Cancer

An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis

OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis

Post-Market Real-World Evidence Registry for the NeuroOne OneRF® Ablation System for Epilepsy

Super-Supporters - Virtual Care Technology Navigators